We recently compiled a list of the 8 Good Stocks To Buy Right Now. In this article, we are going to take a look at where ...

This week, Johnson & Johnson JNJ began the third-quarter earnings season for the drug and biotech sector. The FDA granted ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors - making it the first antitissue-factor pathway inhibitor to be allowed for ...

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...

Pfizer (NYSE: PFE) stock jumped 3.1% through 11:20 a.m. ET Monday morning in response to a Wall Street Journal article over ...

About 10%-20% of prostate cancer patients develop mCRPC within 5 to 7 years of diagnosis, according to Pfizer. The Talzenna-Xtandi combination was approved by the U.S. Food and Drug Administration ...

With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...